HER-2 Protein Overexpression clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for

  • ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors

    Sorry, in progress, not accepting new patients

    This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.

    Los Angeles, California and other locations

Last updated: